4
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Production of IFN-? is impaired in patients with paracoccidioidomycosis during active disease and is restored after clinical remission

, &
Pages 225-229 | Published online: 09 Jul 2009
 

Abstract

Cellular immunity is usually suppressed during paracoccidioidomycosis (PCM) and is restored after treatment. In this study we evaluated the induction of a type 1 (interferon γ (IFN-γ)), a type 2 (interleukin (IL)-10) and a primarily macrophage derived cytokine (tumor necrosis factor (TNF)-α) in peripheral blood mononuclear cells (PBMC) from patients with PCM. Eight male patients with active PCM, nine male patients with clinical remission of the disease and 10 healthy control subjects were enrolled in the study. Cytokines were induced with non-specific stimuli -- phytohaemagglutin (PHA) (induces IL-10 and IFN-γ), Lipopolysaccharide (induces TNF-α) -- and Paracoccidioides brasiliensis antigen (PbAg) (induces IL-10, IFN-g and TNF-a). Induction of IFN-g with PHA differed among the three groups (P<0·01; Kruskal-Wallis test) and with PbAg was lower in patients with active disease compared to those in clinical remission (P=0·05; Mann-Whitney). Induction of IL-10 and of TNF-α was similar in the three groups. The suppressed production of IFN-γ in patients with active disease may underscore the cellular immune deficiency seen in these patients.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.